Prevalence of Elevated Blood Pressure in Type-2 DiabeticsNCT05266885
Prevalence of Hypertension in Type-2 Diabetes Mellitus
An observational study of Prevalence of Elevated Blood Pressure in Type-2 Diabetics, run by Kabul University of Medical Sciences at 1 site in Afghanistan.
Trial summary
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Prevalence of Elevated Blood Pressure in Type-2 Diabetics
- How many people
- 322 participants
- Where
- 1 siteAfghanistan
- Study dates
- 1 Nov 2019to 30 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All Type -2 diabetics who were presented to our center from November 2019 to January 2020.
Who may be able to join
- Clinically diagnosed diabetic patients
- Newly diagnosed Diabetics
- known case of diabetes
Who cannot join
- The patients who were seriously ill
- Pregnant women
- Type-1 diabetic patients,
Trial locations and contacts
1 site in 1 country.
About this study
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.
Read the detailed description
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.
This is a descriptive cross-sectional study, which included 322 type -2 diabetic patients (37 male, 63 female) who were presented to our center from November 2019 to January 2020.
- Keywords
- Prevalence; Hypertension; Type-2 diabetes
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Male and Female | (37 male, 63 female) |
What is being measured
The primary outcome is the main question the study is designed to answer.
High incidence of HTN in Diabetics
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2022
- Study start1 Nov 2019
- Primary completion1 Jan 2020
- Study completion30 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prevalence of Elevated Blood Pressure in Type-2 DiabeticsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 322 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kabul University of Medical Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Habib Ahmad Esmat, Kabul University of Medical Sciences
- Investigators
- Mohammad wali Nasary, MD, Principal investigator, KMUs
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05266885
- Sponsor's protocol ID
- 0003
- Status last verified
- Mar 2022
- First submitted
- 20 Feb 2022
- Last updated
- 4 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Hypertension in Type-2 Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT05266885
- Acronym / sponsor ID
- 0003
- Keywords
- Prevalence; Hypertension; Type-2 diabetes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 322 participants (actual)
- Lead sponsor
- Kabul University of Medical SciencesUniversity, hospital or other
- Study start
- 1 Nov 2019 (actual)
- Primary completion
- 1 Jan 2020 (actual)
- Study completion
- 30 Jan 2020 (actual)
- First posted
- 4 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.
Detailed description
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.
This is a descriptive cross-sectional study, which included 322 type -2 diabetic patients (37 male, 63 female) who were presented to our center from November 2019 to January 2020.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Male and Female | – | –(37 male, 63 female) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All Type -2 diabetics who were presented to our center from November 2019 to January 2020.
Key inclusion criteria (3 listed)
- Clinically diagnosed diabetic patients
- Newly diagnosed Diabetics
- known case of diabetes
Key exclusion criteria (3 listed)
- The patients who were seriously ill
- Pregnant women
- Type-1 diabetic patients,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
High incidence of HTN in Diabetics
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2022.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohammad wali Nasary, MD principal investigator
KMUs
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prevalence of Elevated Blood Pressure in Type-2 Diabetics, run by Kabul University of Medical Sciences at 1 site in Afghanistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Afghanistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
High incidence of HTN in Diabetics (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2022.